NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Descending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00085-4350-01 | 00085-4350 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
00085-4351-01 | 00085-4351 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
00085-4352-01 | 00085-4352 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
73536-0500-01 | 73536-0500 | ROPEGINTERFERON ALFA-2B | BESREMi | 500.0 ug/mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Nov. 12, 2021 | In Use | |
49663-0001-06 | 49663-0001 | Cysteamine bitartrate | PROCYSBI | 25.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | April 30, 2013 | Feb. 28, 2019 | No Longer Used | |
49663-0002-25 | 49663-0002 | Cysteamine bitartrate | PROCYSBI | 75.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | April 30, 2013 | Feb. 28, 2019 | No Longer Used | |
75987-0140-13 | 75987-0140 | Cysteamine bitartrate | PROCYSBI | 75.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Feb. 14, 2020 | In Use | ||
75987-0140-14 | 75987-0140 | Cysteamine bitartrate | PROCYSBI | 75.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Feb. 14, 2020 | In Use | ||
75987-0145-13 | 75987-0145 | Cysteamine bitartrate | PROCYSBI | 300.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Feb. 14, 2020 | In Use | ||
75987-0145-14 | 75987-0145 | Cysteamine bitartrate | PROCYSBI | 300.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Feb. 14, 2020 | In Use | ||
00378-9040-01 | 00378-9040 | Cysteamine bitartrate | Cystagon | 50.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Aug. 15, 1994 | Sept. 4, 2018 | In Use | |
00378-9040-05 | 00378-9040 | Cysteamine bitartrate | Cystagon | 50.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | April 11, 2005 | In Use | ||
00378-9045-01 | 00378-9045 | Cysteamine bitartrate | Cystagon | 150.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Aug. 15, 1994 | Sept. 4, 2018 | In Use | |
00378-9045-05 | 00378-9045 | Cysteamine bitartrate | Cystagon | 150.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | April 11, 2005 | In Use | ||
00069-0688-03 | 00069-0688 | palbociclib | Ibrance | 125.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
00069-0486-03 | 00069-0486 | Palbociclib | Ibrance | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
73462-0101-01 | 73462-0101 | Trilaciclib | Cosela | 300.0 mg/20mL | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Intravenous | Feb. 12, 2021 | In Use | |
00002-5337-54 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00002-5337-63 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 5, 2020 | In Use | |
00069-0284-03 | 00069-0284 | Palbociclib | Ibrance | 75.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
00002-4815-54 | 00002-4815 | Abemaciclib | Verzenio | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00002-6216-54 | 00002-6216 | Abemaciclib | Verzenio | 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00069-0187-21 | 00069-0187 | Palbociclib | Ibrance | 75.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Feb. 3, 2015 | In Use | |
00069-0188-21 | 00069-0188 | Palbociclib | Ibrance | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Feb. 3, 2015 | In Use | |
00069-0189-21 | 00069-0189 | Palbociclib | Ibrance | 125.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Feb. 3, 2015 | In Use |
Found 10,000 results in 7 milliseconds — Export these results